Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone Continuation Study
NCT01485640Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in schizophrenia and bipolar disorder (BD), sponsored by Sumitomo Pharma America. Primary endpoint: Treatment Emergent Adverse Events at 18 months. Started Jun 2011; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT01485640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01485640.